Evommune is stopping EVO756 development in atopic dermatitis after its Phase 2b trial failed to meet primary and secondary endpoints. The company will continue evaluating EVO756 for migraine prophylaxis, while EVO301 is planned for an atopic dermatitis Phase 2b trial in mid-2027 and operations are expected to remain funded into 2029.

Key Highlights

  • EVO756’s Phase 2b trial did not meet its primary or secondary endpoints in any dose studied.
  • Evommune plans to cease EVO756 development in atopic dermatitis and continue evaluating it in migraine prophylaxis.
  • EVO301 is planned to enter an atopic dermatitis Phase 2b trial in mid-2027.

Evommune, Inc. (NYSE: EVMN) will stop developing EVO756 for atopic dermatitis after the treatment failed to meet the primary and secondary endpoints in its Phase 2b trial. The company will continue evaluating the oral MRGPRX2 antagonist in migraine prophylaxis.

Participants received treatment during the trial period and were followed afterward through the stated follow-up assessment. The study also missed its secondary endpoints across the doses studied.

EVO301 Becomes Lead Atopic Dermatitis Program

EVO301, described by Evommune as an IL-18BP fusion protein, is advancing as the company’s lead atopic dermatitis program after positive Phase 2a proof-of-concept data. A Phase 2b trial for EVO301 is planned for mid-2027. EVO756 remains under evaluation for migraine prophylaxis. Based on its current business plans and revised clinical development plans, Evommune expects its cash, cash equivalents and investments to fund operations into 2029.